Table 1. Baseline characteristics and clinical outcomes.
| Baseline characteristics of the entire cohort (n = 4,632) | ||
|---|---|---|
| Age (year) | ||
| Median (IQR) | 63 (54–71) | |
| Race | ||
| White Americans | 3,910 | 84% |
| Black Americans | 516 | 11% |
| Other and unknown | 206 | 5% |
| Sex | ||
| Female | 2,739 | 59% |
| Male | 1,893 | 41% |
| BMI (kg/m2) | ||
| Median (IQR) | 27 (23–32) | |
| ≥30 | 1,610 | 35% |
| <25 | 1,645 | 36% |
| 25–29.9 | 1,377 | 30% |
| Tobacco | 2,317 | 50% |
| Family history | 1,654 | 36% |
| Comorbidities | ||
| Hypertension | 2,622 | 57% |
| Hyperlipidemia | 2,010 | 43% |
| Diabetes | 1,039 | 22% |
| Malignancy | ||
| Hematologic cancer | 1,822 | 39% |
| Solid tumor cancer | 2,810 | 61% |
| Clinical endpoints | ||
| Mortality (all cause) | 1,799 | 39% |
| Mortality (in hospital) | 486 | 10% |
| Cardiac events | 1,670 | 36% |
| Pre-existing | 784 | 17% |
| De novo CTRCD | 886 | 19% |
The cohort has 4,632 patients in total. Data for continuous variables were presented as median (IQR), and data for categorical variables were presented as number of percentages, n (%). Cardiac events: 5 hospital diagnosed outcomes by ICD 9/10 codes, including AF, CAD, HF, MI, and stroke. De novo CTRCD: The patient has at least one type of cardiac events diagnosed after cancer therapy.
AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CTRCD, cancer therapy–related cardiac dysfunction; HF, heart failure; IQR, interquartile range; MI, myocardial infarction.